Identification of Nonresponsive Isolates to Glucantime in Patients with Cutaneous Leishmanaisis in Bam

Publish Year: 1390
نوع سند: مقاله ژورنالی
زبان: Persian
View: 18

This Paper With 12 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_JKMU-18-4_002

تاریخ نمایه سازی: 14 اسفند 1402

Abstract:

Background & Aims: Cutaneous leishmaniasis (CL) is a prevalent disease worldwide including Iran. In Iran Leishmania tropica and Leishmania major are two causing factors of cutaneous leishmaniasis and Bam is one of the old and well-known focuses of CL. The objective of the present study was to identify the resistant isolates to meglumine antimoniate (MA) for implementation of future control measures in Bam. Methods: This work has been conducted during ۲۰۰۹-۲۰۱۰ in the city of Bam and Kerman School of Medicine. From a total of ۲۱۲۶ patients with CL, ۲۳۵ patients (۱۱.۱%) were resistant against MA (Glucantime) of whom ۵۱ ones were randomly selected. Skin scrapings were taken for direct smear preparations and culture media and Nested-polymerase chain reaction (PCR) were used for species identification. Findings: In this study, ۱۲۲ males (۵۱.۹%) and ۱۱۳ females (۴۸.۱%), resistant to MA were identified that shows no significant difference between the two sexes. With a significant difference most of the resistant patients were in the age group ۱۱-۲۱ years (۲۹.۴%), followed by ۱۰ years (۲۱.۶%) and the lowest were in the age group ۵۵ years (۵.۹%). Most of the lesions were on face (۵۵.۵%), the majority had one lesion (۶۴.۵%) and ۳۳.۳% received MA intra -lesionally. According to the results of PCR, all ۵۱ isolates were Leishmania tropica. Conclusion: To our knowledge this is the first study that is carried out on the resistant patients to MA in Bam. Since the incidence of this disease and drug resistance have been increased after the earth quake of ۲۰۰۳, further studies to identify genetic variants of resistant isolates in order to use new alternative drugs are required.

Authors

R Pour

M.Sc. Student in Parasitology, Dermatology and Leishmaniasis Research Center, Parasitology and Mycology Dept., Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman, Iran.

I SHarifi

Professor of Parasitology, Dermatology and Leishmaniasis Research Center & Parasitology and Mycology Dept., Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman, Iran.

B Kazemi

Professor of Parasitology, Cellular and Molecular Research Center & Parasitology, School of Medicine, Shahid Baheshti University of Medical Sciences, Tehran, Iran.

M Zarean

Instructor, Dermatology and Leishmaniasis Research Center & Parasitology and Mycology Dept, Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman, Iran